Results 61 to 70 of about 13,620 (98)

The Prognostic Value of Tumor HER2 Expression in Predicting Oncological Outcomes of Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis. [PDF]

Int J Mol Sci
Alibeiginejad MH, Esmaielpour A, Tsuboi I, Matsukawa A, Yanagisawa T, Mori K, Kardoust Parizi M.   +6 more
europepmc   +1 more source

The Utility of HER2 Overexpression in Prognosis of Gastric Cancer: A Systematic Review and Meta-Analysis Study. [PDF]

Cancer Rep (Hoboken)
Pourfaraji SM, Abdollahi A, Shirmard FO, Ghalehtaki R, Salarvand S.   +4 more
europepmc   +1 more source

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol. [PDF]

Cancer Med
Maeda O, Tanaka C, Furukawa K, Miyata K, Shimizu D, Sugita S, Nakanishi K, Hirose T, Mizuno K, Kinoshita F, Kuwatsuka Y, Ando M, Kanda M, Kawashima H, Ando Y.   +14 more
europepmc   +1 more source

Affinity Enhancement in Discrete Multivalent MegaMolecules. [PDF]

Chembiochem
Gu Z, Kimmel BR, Modica JA, Huang CF, Salaria RK, Sridhar S, Kelleher NL, Mrksich M.   +7 more
europepmc   +1 more source

Association of statin use with pathological complete response in postmenopausal patients with hormone receptor-positive breast cancer. [PDF]

Sci Rep
Ersoy M.
europepmc   +1 more source

Impact of breast cancer characteristics on the development and time to liver metastases: population-based study. [PDF]

BJS Open
Sundén M, Lindqvist E, Wahlqvist E, Hansson E, Wadsten C, Andersson A, Sund M, Hemmingsson O.   +7 more
europepmc   +1 more source

Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer. [PDF]

J Comp Eff Res
Watkins C, Simon C, Martin P, Leadley R, Redhead G, Neuberger E, Bartley K.   +6 more
europepmc   +1 more source

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic <i>HER2</i>-Mutant Non-Small Cell Lung Cancer. [PDF]

JCO Precis Oncol
Lovly CM, Baik C, Nagasaka M, Patil T, Maruti SS, Stanhope S, Kaya NA, Herbertz S, Nordstrom B, Evans K, Le X.   +10 more
europepmc   +1 more source

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study. [PDF]

Cancer Med
Kuang M, Li J, Bian L, Zhang S, Wang T, Tong Z, Ouyang Q, Jiang Z.   +7 more
europepmc   +1 more source

The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer. [PDF]

Breast Cancer Res Treat
Gaba AG, Cao L, Renfrew RJ.
europepmc   +1 more source